Understanding the Class Action Against Pacira Biosciences
Recently, Lowey Dannenberg P.C., a notable law firm recognized for advocating on behalf of investors, has taken significant legal action against Pacira Biosciences, Inc. (NASDAQ: PCRX). This class action lawsuit is a response to serious allegations regarding potential violations of federal securities laws that could impact investors who suffered substantial financial losses due to misleading statements from the company.
Details of the Allegations
The class action pertains to a specific period when many investors acquired shares of Pacira. Allegations indicate that the company, along with certain officers, misrepresented the strength of its patent protections for Exparel, a product critical to its revenue stream. Pacira was accused of creating false assumptions about the extent of patent safeguards, which they asserted were substantial enough to facilitate growth in marketing and sales.
A crucial turning point occurred when it was revealed that the company was aware of the weaknesses in their patent strategy. A court ruling that favored eVenus Pharmaceutical Laboratories signified a serious blow to Pacira’s claims about its patent protections. This led to a state of shock among analysts and investors alike when the significant news broke about the invalidation of a critical patent, raising concerns that competitors could enter the market during that patent's lifespan.
The Impact on Investors
Public knowledge of these misleading statements has resulted in a drastic decline in Pacira’s stock value, causing pronounced losses for investors. Specifically, if you are one of the shareholders who have suffered losses exceeding $100,000, you may have options for legal recourse and compensation.
Joining the Class Action
Investors wishing to join the class action or those seeking more information can directly reach out to the law firm involved in the case. Their team is prepared to assist injured investors and guide them through the process of potentially recouping their losses.
Who is Lowey Dannenberg?
Lowey Dannenberg is known for its dedication to representing both institutional and individual investors who face financial difficulties due to corporate misconduct and violations of securities laws. Their experience includes handling multi-million-dollar lawsuits and recovering significant sums for clients. This expertise plays a crucial role in representing Pacira’s investors in this situation.
Contact Information
If you are interested in pursuing a claim or wish to learn more about your rights as an investor, you can contact Lowey Dannenberg P.C. Their office is located at 44 South Broadway, Suite 1100, White Plains, NY 10601. You can reach them by phone at (914) 733-7256 or send an email to Andrea Farah or Vincent R. Cappucci Jr.
Frequently Asked Questions
What is the basis for the class action lawsuit against Pacira?
The lawsuit cites misleading statements regarding Pacira’s patent protections for Exparel, which potentially misled investors about the company’s financial health.
Who can join the class action lawsuit?
Investors who incurred losses greater than $100,000 in Pacira’s securities during the specified class period are eligible to join the lawsuit.
Who is representing the investors in this case?
The law firm Lowey Dannenberg P.C. is representing the investors in the class action lawsuit.
How can I contact Lowey Dannenberg for more information?
You can reach Lowey Dannenberg by calling (914) 733-7256 or emailing Andrea Farah or Vincent R. Cappucci Jr. for assistance.
What should I do if I want to participate in the class action?
It is crucial to contact the law firm promptly to discuss your situation and get involved in the class action process.
